SAN FRANCISCO — Decrease in IOP as well as medication burden was sustained over a 12-month period in eyes implanted with the Xen45 gel stent, according to a poster presented at the American Glaucoma Society annual meeting.
Davinder S. Grover , MD, MPH, and colleagues conducted a retrospective study evaluating surgical outcomes after Xen45 (Allergan) implantation in patients at a single glaucoma subspecialty practice since the FDA approval of the device in 2016 for surgical management of refractory glaucoma.
The gel stent was implanted in one eye of each of (Read more...)
Uncategorized